What side effects were reported with tesamorelin?
The “Marcus” story was presented like a real patient account, but no source or verified interview supported it. It has been removed. Current EGRIFTA SV prescribing information reports adverse reactions observed in clinical studies; it does not describe that individual, his symptoms, or the stated IGF-1 result.
Adverse reactions reported in clinical studies
The label identifies arthralgia, injection-site erythema and pruritus, pain in an extremity, peripheral edema, and myalgia as the most commonly reported adverse reactions. In its pooled 26-week table, injection-site reactions were reported in 17% versus 6% with placebo, arthralgia in 13% versus 11%, pain in an extremity in 6% versus 5%, myalgia in 6% versus 2%, and peripheral edema in 6% versus 2%.
| Reaction | Tesamorelin | Placebo |
|---|---|---|
| Injection-site reactions | 17% | 6% |
| Arthralgia | 13% | 11% |
| Pain in extremity | 6% | 5% |
| Myalgia | 6% | 2% |
| Peripheral edema | 6% | 2% |
The label also discusses fluid retention, elevated IGF-1, glucose intolerance or diabetes, hypersensitivity, and injection-site reactions. Population and formulation matter; these rates are not a personal prediction.
Primary source
Current DailyMed prescribing information for EGRIFTA SV.
From the FormBlends catalog
Tesamorelin
GHRH analog studied for visceral-fat reduction; the molecule was approved as Egrifta · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Tesamorelin →
Ready when you are
Tesamorelin
GHRH analog studied for visceral-fat reduction; the molecule was approved as Egrifta · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Tesamorelin →